Gelesis Holdings, Inc. (GLS) Stock

About Gelesis Holdings, Inc.

Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Established in 2006, Gelesis Holdings Inc. operates from its headquarters in Boston, Massachusetts.

Gelesis Holdings, Inc. is headquartered in US.

Gelesis Holdings, Inc. (GLS) stock trades at $0.16 with a market capitalization of $11.63M. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-book of -0.44, price-to-sales of 0.45. Over the past 52 weeks the stock has ranged between $0.01 and $5.67, and currently trades 97.2% below its 52-week high.

On profitability, Gelesis Holdings, Inc. generates a return on equity (ROE) of 31.43% — well above the market average, a sign of a high-quality business, return on capital employed of -231.39%, an operating margin of -472.72%, a net profit margin of -216.48%.

Official website: www.gelesis.com